A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer’s Disease.
A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer’s
Phase 2 Study of BIIB092 in Participants With Early Alzheimer’s Disease (TANGO).
Clinical trial of Sailuotong (SLT) for Vascular Dementia or Alzheimer’s Disease with evidence of cerebrovascular disease trial
Randomized, Double-Blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer’s Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine.
An Extension Study of ANAVEX2-73 in Patients with Mild to Moderate Alzheimer’s Disease.
A Phase III, multicentre, randomised, Double-Blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in participants with Prodromal to mild Alzheimer’s disease. (Protocol: BN29553) Cread 2
Anti-Amaloid Treatment in Asymptomatic Alzheimer’s Disease.
A Phase 3, double blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease.
A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease.
A Phase III, multicentre, randomised, double blind, placebo-controlled, parallel-group, efficacy and safety study with open label extension of Chrenexumab in patients with prodromal-rodromal -to mild Alzheimer’s disease
A Phase III, randomised, double blind, placebo-controlled, parallel-group multicentre efficacy and safety study of Gantenerumab in patients with mild Alzheimer’s disease.
Study title: Mutlicentre, randomised, double blind, placebo controlled, parallel group two year study to evaluate the effect of subcutaneous RO4909832 on cognitive and function in prodromal Alzheimer’s Disease.
Clinical Study No. RVT-101-3002, A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer’s Disease.
A Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design with Repeated Doses, Maximum Tolerated Dose Finding, Pharmacodynamic Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer’s Disease With a 6-Month Open Label Follow-Up Period.
New Takeda AD-4833 TOMM40_303 Study – extension study.
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects.
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).
A multicentre, randomised, double-blind, placebo-controlled, Phase 2 study comparing 3mg and 12mg of LY3202626 with placebo over 52 weeks in approximately 500 patients with mild Alzheimer’s disease dementia (NAVIGATE-AD).
A Randomized, Double-Blind, Placebo-Controlled, Phase I Study Of The Safety And Pharmacokinetics Of Two Doses Of Ct1812 In Subjects With Mild To Moderate Alzheimer’s Disease.
Astra Zeneca, D5010C00009, A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Outpatients with Early Alzheimer’s Disease; PAREXEL number 216846.
A clinical trial to determine the safety and efficacy of MK-8931 in Mild to Moderate Alzheimer’s Disease. (EPOCH).
‘Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo.
Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3.
A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication.
A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication.
A phase III safety and efficacy study of ALZT‐OP1 in subjects with evidence of early Alzheimer’s disease.
A Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Multi-Center Study to Evaluate the Safety , Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of F03 in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease
Continued efficacy and safety monitoring of solanezumab, an anti-amyloid antibody in patients with Alzheimer’s Disease.
A Phase II, multicentre, randomised, double blind, parallel-group, placebo controlled study to investigate the efficacy and safety of RO4602522 added to background Alzheimer’s Disease therapy in patients with moderate severity Alzheimer’s Disease.
A Randomised, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer’s Disease (Protocol PBT2-204).
Randomised, double blind, placebo controlled, parallel group, 12 month trial of Leuco-methylthioninium bis(hydromethanesulfonate) in subjects with mild to moderate Alzheimer’s Disease.
An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia.
EARLY: A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicentre Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer’s Dementia.
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of 35 mg twice daily Xanamem™ in Subjects with mild dementia due to Alzheimer’s Disease (AD).
ENGAGE: A phase 3 Multicentre, randomised, double blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of BIIB037 in subjects with early symptomatic Alzheimer’s Disease
MISSION AD1: Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease.
A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer’s Disease
A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer’s Disease.
A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of Two Amyloid Lowering Agents, CAD106 and a BACE 1 Inhibitor, on Postponing Cognitive Decline in Cognitively Unimpaired APOE4 Homozygotes Elderly Subjects at Risk for the Onset of Clinical Symptoms due to Alzheimer Disease.
Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer’s Disease.